Parkinson's disease (PD) is a neurodegenerative disorders characterized by a progressive loss of dopaminergic neurons of substantia nigra pars compacta with motor dysfunctions. The etiology of PD is yet unknown, and there is no cure available. Although various pharmacotherapies are modestly successful, late complications of the therapies limit the ultimate utility. We propose the use of genetically modified primary skin fibroblasts that produce catecholamines or neurotrophic factors as donor cells for grafting in rat models of PD. The primary dermal fibroblasts can be biopsied easily and grown well in culture. These primary fibroblast can be genetically modified by retroviral vectors with high efficiency. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase, basic fibroblast growth factor, and brain derived neurotrophic factor will be introduced by this method. The transduced fibroblasts will be examined in vitro to characterize the expression of these transgenes and their biological functions. These cells will then be grafted in the brain to assess the survival, host reactions, and transgene expression in vivo. Once fully characterized, these cells will be studied for functional effects in rat models of PD. The catecholamine-producing cells will be tested for their ability to ameliorate the apomorphine-induced rotational behavior in rats with unilateral lesions of the substantia nigra. The neurotrophic factor- producing fibroblasts will be studied for their ability to promote sprouting and survival of the remaining dopaminergic neurons, and their effect on behavioral recovery. In the future, combinations of both neurotransmitter replacement and neurotrophic factor delivery strategies will also be studied.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG008514-04
Application #
3567369
Study Section
Neurology B Subcommittee 2 (NEUB)
Project Start
1989-07-01
Project End
1996-06-30
Budget Start
1992-09-01
Budget End
1993-06-30
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Singer, Oded; Marr, Robert A; Rockenstein, Edward et al. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8:1343-9
Hashimoto, M; Rockenstein, E; Mante, M et al. (2004) An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 11:1713-23
Lie, D Chichung; Song, Hongjun; Colamarino, Sophia A et al. (2004) Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 44:399-421
Pizzo, Donald P; Paban, Veronique; Coufal, Nicole G et al. (2004) Long-term production of choline acetyltransferase in the CNS after transplantation of fibroblasts modified with a regulatable vector. Brain Res Mol Brain Res 126:1-13
Hashimoto, Makoto; Kawahara, Kohichi; Bar-On, Pazit et al. (2004) The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J Mol Neurosci 24:343-52
Marr, Robert A; Rockenstein, Edward; Mukherjee, Atish et al. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23:1992-6
Hashimoto, Makoto; Rockenstein, Edward; Crews, Leslie et al. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4:21-36
Dickinson-Anson, Heather; Winkler, Jurgen; Fisher, Lisa J et al. (2003) Acetylcholine-secreting cells improve age-induced memory deficits. Mol Ther 8:51-61
Horner, Philip J; Gage, Fred H (2002) Regeneration in the adult and aging brain. Arch Neurol 59:1717-20
Lie, D Chichung; Dziewczapolski, Gustavo; Willhoite, Andrew R et al. (2002) The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 22:6639-49

Showing the most recent 10 out of 40 publications